Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

VOLUNTARY ANNOUNCEMENT
VOLUNTARY LOCK-UP UNDERTAKING BY CONTROLLING SHAREHOLDERS NOT TO DISPOSE OF SHARES FOR TWELVE MONTHS FROM THE DATE OF THIS ANNOUNCEMENT

This announcement is made by Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**Haixi Pharmaceuticals**") on a voluntary basis to inform the shareholders and potential investors of the Company of the voluntary lock-up undertaking given by the controlling shareholders of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that Dr. Kang Xinshan and Ms. Feng Yan, the founders and controlling shareholders of the Company, who are spouses and parties acting in concert (together, the "**Controlling Shareholders**"), have voluntarily undertaken that, during the period of twelve (12) months commencing from the date of this announcement (the "**Lock-up Period**") to and including 5 November 2027, they will not sell, transfer or otherwise dispose of any shares of the Company respectively held directly by them (the "**Voluntary Lock-up Undertaking**").

As of the date of this announcement, Dr. Kang Xinshan directly holds 12,759,114 shares of the Company (approximately 16.21% of the total issued share capital of the Company) and Ms. Feng Yan directly holds 9,918,426 shares (approximately 12.60%), aggregating 22,677,540 shares (approximately 28.81%). The Voluntary Lock-up Undertaking covers all of the shares directly held by the Controlling Shareholders as set out above. Dr. Kang Xinshan also indirectly holds 5,000,000 shares (approximately 6.35%) through Xiamen Tairuihe Investment Partnership (Limited Partnership) ("**Tairuihe Investment**"). Tairuihe Investment is an employee stock ownership platform of the Group, the limited partnership interests of which are held by employees of the Group, and Dr. Kang Xinshan is its sole general partner and executive partner and is entrusted with the management of the platform. Such shares

are not within the scope of the Voluntary Lock-up Undertaking. The said Voluntary Lock-up Undertaking constitutes an additional voluntary undertaking by the Controlling Shareholders, which is in addition to the lock-up obligations of the Controlling Shareholders under applicable laws and regulations and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board believes that the Voluntary Lock-up Undertaking demonstrates the Controlling Shareholders' confidence in the long-term development prospects of the Company and their commitment to aligning their interests with those of the Company and all its shareholders.

INFORMATION ON HAIXI PHARMACEUTICALS

Haixi Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of innovative drugs, striving to develop innovative drug products with clinical value for the treatment of oncology, ophthalmology and other major diseases. The Company continuously advances the global clinical development and commercialisation layout of its innovative drugs to address clinical needs that have not been fully satisfied. The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited in October 2025 (stock code: 2637).

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 5 November 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming, Mr. Li Junqing and Mr. Chen Tingze as executive Directors; (ii) Mr. Xu Dong as non-executive Director; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.